Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Business
Leo Miller

Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?

And two Wall Street analysts believe shares could go even higher.

BTIG Research and HC Wainwright updated their price targets on the stock to $100 and $120, respectively. As of June 24, the MarketBeat-tracked consensus price target on Nektar was around $76, implying 212% upside. However, when taking these two new targets into account, shares could rise by 349%.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.